Introduction {#S0001}
============

Ovarian cancer is the deadliest cancer among gynaecological malignancies.[@CIT0001] This disease is usually asymptomatic and difficult to detect in the early stages.[@CIT0002] At present, surgery and chemotherapy are the main treatments for ovarian cancer. However, relapse rates and drug resistance are high, and the prognosis is poor, especially for advanced patients. The 5-year survival rate of ovarian cancer is less than 40%.[@CIT0003] Sensitive early detection indicators and new therapeutic targets are urgently needed to improve the status quo.[@CIT0002],[@CIT0004]

Long noncoding RNAs (lncRNAs) are stable noncoding RNAs that are greater than 200 nucleotides in length[@CIT0005] Many lncRNAs are expressed at low levels and have fairly high tissue or cell-type specificity.[@CIT0006] MicroRNAs (miRNAs) are a type of endogenous noncoding RNA with approximately 20 nucleotides and various regulatory functions and can inhibit translation and promote degradation of target mRNAs.[@CIT0007] Recent research has shown that lncRNAs can regulate gene expression by titrating miRNAs in a phenomenon known as the competing endogenous RNA (ceRNA) hypothesis[@CIT0008] (also known as the "sponge" function)[@CIT0009] to participate in various biological processes. For example, Grelet et al[@CIT0010] found that the lncRNA PNUTS can act as a sponge for miR-205 during the epithelial-mesenchymal transition of tumour cells. Chen et al[@CIT0011] found that the lncRNA UICLM acts as a ceRNA for miR-215 to regulate the expression of ZEB2 and thereby control colorectal cancer liver metastasis. However, the specific mechanisms of many lncRNAs remain obscure. FLJ33360 (LINC02145/CTD-2324F15.2) is located on 7p15.2, with the NCBI Gene ID 401172. At present, no reports on related functions have been published.

In this study, we first found that FLJ33360 was significantly downregulated in ovarian cancer tissues. To further explore the clinical significance and potential molecular mechanism of FLJ33360 in ovarian cancer, we conducted in-depth studies in combination with qRT-PCR, meta-analysis and bioinformatics. The flow chart is shown in [Figure 1](#F0001){ref-type="fig"}.Figure 1A flow chart of this study.

Materials and methods {#S0002}
=====================

Human samples {#S0002-S2001}
-------------

A total of 32 ovarian cancer specimens and 31 normal ovarian specimens were collected from the Department of Obstetrics and Gynecology in People's Hospital of Zhengzhou University between January 2018 and October 2018. Cancer specimens were collected from ovarian cancer patients undergoing cytoreductive surgery, and healthy ovarian tissue was collected from patients undergoing adnexectomy due to myoma or uterine prolapse. The patients ranged in age from 28 to 74 years with a mean age of 55 years. Cancer tissues were collected from primary sites, and the healthy ovarian tissues were collected from the surface epithelium. Fresh tissues were frozen in liquid nitrogen within 5 mins after excision and transferred to a −80 °C freezer. No patients received any pre-operative therapy. All experimental protocols were approved by the Ethical Committee of the People's Hospital of Zhengzhou University, and the clinicians and patients signed the consent forms for the use of their tissues in the study. Histopathology and clinical data were extracted from pathology reports and medical records.

Quantitative reverse-transcription PCR {#S0002-S2002}
--------------------------------------

Total RNA was extracted from the tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription of 1 µg of total RNA into cDNA was performed using a Thermo Scientific Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA). Quantitative real-time PCR amplification of cDNA was performed with PowerUpTM SYBRTM Green Master Mix (Applied Biosystems, Foster city, CA, USA). For the Applied Biosystems 7500 System, the thermal cycling conditions were 94 °C for 30 sec, followed by 40 cycles for 94 °C for 5 sec and 60 °C for 30 sec. The expression of FLJ33360 relative to β-actin expression was determined using the 2-ΔΔCT method. The primers used were FLJ33360 (forward) 5ʹ-GCTTCCGATGTGCTGTGGTA-3ʹ and FLJ33360 (reverse) 5ʹ-CTGTCTGGGAGGATGGATGTC-3ʹ, β-actin (forward)

5ʹ-CCTGTACGCCAACACAGTGC-3ʹ and β-actin (reverse)

5ʹ-ATACTCCTGCTTGCTGATCC-3ʹ.

The Cancer Genome Atlas (TCGA), Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier Plotter databases and data collection {#S0002-S2003}
------------------------------------------------------------------------------------------------------------------------------------------

We analysed RNA-Seq data from individuals with ovarian cancer from the Illumina HiSeq RNASeq platform using the TCGA data portal (<https://tcga-data.nci.nih.gov/tcga/>), which contained 374 ovarian cancer tissues and no healthy ovarian tissue samples. The expression level of the desired RNA was normalized by the Deseq package of the R language for further analysis.

GEPIA (<http://gepia.cancerpku.cn/>) is an interactive website based on TCGA and Genotype-Tissue Expression (GTEx) project data. We extracted GEPIA data to obtain FLJ33360 expression profiles of various types of human cancer and adjacent normal tissues and validated the differential expression of FLJ33360 in ovarian cancer and healthy ovarian tissues. In addition, GEPIA data were used to analyse differences in FLJ33360 expression at different FIGO stages in ovarian cancer patients.

The online database Kaplan-Meier Plotter (KM plotter, <http://kmplot.com>) was used to assess the association between FLJ33360 expression levels and progression-free survival (PFS), which includes FLJ33360 expression and prognosis information for 614 ovarian cancer patients. The patients were stratified according to the median FLJ33360 expression level (high vs low expression). The hazard ratio (HR) with 95% confidence intervals (CIs) and *P*-value were calculated by a PostgreSQL server. *P*\<0.05 was considered significant.

Target gene prediction {#S0002-S2004}
----------------------

Four prediction algorithms, including DIANA IncBase v2[@CIT0012] (<http://diana.imis.athena-innovation.gr/>), RegRNA2.0[@CIT0013] (<http://regrna2.mbc.nctu.edu.tw/detection.html>), miRDB[@CIT0014] (<http://mirdb.org/>) and IncRNAMap[@CIT0015] (<http://lncrnamap.mbc.nctu.edu.tw/php/>), were used to predict miRNAs that interact with FLJ33360. A total of five target prediction algorithms were used to predict the potential target genes of miRNA. The five corresponding prediction algorithms were miRWalk[@CIT0016] (<http://mirwalk.umm.uni-heidelberg.de/>), DIANA Tarbase v8[@CIT0017] (<http://carolina.imis.athena-innovation.gr>), miRDB (<http://mirdb.org/>), miRMap[@CIT0018] (<http://mirmap.ezlab.org/>) and miRTarBase[@CIT0019] (<http://mirtarbase.mbc.nctu.edu.tw/php/search.php>). Venn diagrams were used to identify overlapping target genes (<http://bioinformatics.psb.ugent.be/webtools/Venn/>).

Selection of microarrays in Gene Expression Omnibus (GEO) and ArrayExpress datasets {#S0002-S2005}
-----------------------------------------------------------------------------------

Ovarian cancer-related microarrays were downloaded from the National Center of Biotechnology Information (NCBI) GEO (<http://www.ncbi.nlm.nih.gov/geo/>) and European Bioinformatics Institute's (EBI) ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/>) database. The search keywords were as follows: miRNA and mRNA and (malignant\* OR cancer OR tumor OR neoplasm\* OR carcinoma) and (oophoroma OR ovarian OR OV). The retrieval date was up to October 1, 2018. The screening criteria included (1) corresponding miRNA or mRNA expression in ovarian cancer and normal ovarian samples that can be detected; (2) study samples from human tissue, cell lines, exosomes or body fluids; and (3) more than 3 subjects per group.

Meta-analysis {#S0002-S2006}
-------------

Stata 14.0 (Stata Corp., College Station, TX, USA) was used for the meta-analysis of miRNA microarrays in this study. Heterogeneity among the included studies was assessed by the chi-squared and I-squared tests. A fixed effects model was selected when the heterogeneity was low (I^2^≤50% and *P*\>0.05), and when heterogeneity was significant, a random effects model was selected (I^2^\>50% or *P*≤0.05). A funnel plot was used to detect a publication bias.

Functional analysis of target genes {#S0002-S2007}
-----------------------------------

We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses using the GluGO plug-in Cytoscape 3.6.1.[@CIT0020],[@CIT0021] The STRING database[@CIT0022] (<http://string-db.org>) provides a critical assessment and integration of protein-protein interactions (PPIs) by combining a large amount of known and predicted protein-protein association data. We used the STRING website to build the PPI network.

Statistical analysis {#S0002-S2008}
--------------------

Statistical analysis was performed using SPSS 22.0 (IBM, Chicago, IL, USA) and GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA, USA). Student's *t*-test was used to analyse differences between the two groups. The receiver operating characteristic (ROC) curve was used to predict the diagnostic potential of FLJ33360 in ovarian cancer. Pearson correlation analysis was used to study the correlation between FLJ33360 and BCL2 or DLG2. A *P*-value \<0.05 was considered significant.

Results {#S0003}
=======

Expression and clinical value of FLJ33360 in ovarian cancer {#S0003-S2001}
-----------------------------------------------------------

The GEPIA results showed that FLJ33360 was differentially expressed in a variety of tumours and healthy tissues, with differences in ovarian cancer being particularly pronounced ([Figure 2A](#F0002){ref-type="fig"}). A total of 88 healthy ovarian tissues and 426 ovarian cancer tissues were included in the study, and the results showed that FLJ33360 expression in ovarian cancer was significantly downregulated (*P*\<0.05, [Figure 2B](#F0002){ref-type="fig"}). In addition, with the progression of the disease FIGO stage, FLJ33360 expression was significantly decreased (*P*\<0.05, [Figure 2C](#F0002){ref-type="fig"}). The Kaplan-Meier curve showed that FLJ33360 was closely related to PFS in ovarian cancer patients. Patients with low FLJ33360 expression had a higher recurrence rate than those with high expression (*P*\<0.05, [Figure 2D](#F0002){ref-type="fig"}). To further validate this differential expression, we collected 32 ovarian cancer tissues and 31 healthy ovarian tissues. The PCR results showed that FLJ33360 expression was significantly different (*P*=0.0011, [Figure 2E](#F0002){ref-type="fig"}). The correlations between the FLJ33360 expression level and clinical pathological features of ovarian cancer patients are shown in [Table 1](#T0001){ref-type="table"}. The expression level of FLJ33360 has no association with age and tumour size (all *P*\>0.05). Compared with low-grade serous carcinoma and others, FLJ33360 expression was markedly reduced in high-grade serous carcinoma (*P*=0.027). Compared with the I/II stage, FLJ33360 expression was significantly decreased in the III/IV stage (*P*=0.027). The ROC curve analysis results showed that the area under the curve (AUC) was 0.793 (95% CI: 0.663--0.923) (*P*\<0.001, [Figure 2F](#F0002){ref-type="fig"}).Table 1The correlations between FLJ33360 expression and clinicopathological parameters of ovarian cancer patientsClinicopathological featuresCasesFLJ33360 expression*P*Age (years) ≤5090.66±0.580.442 \>50230.50±0.52Histological type Low-grade serous carcinoma and others70.93±0.480.027 High-grade serous carcinoma250.44±0.50Clinical stage I/II51.02±0.580.027 III/IV270.46±0.48Tumour size (cm) \<10170.58±0.580.725 ≥10150.51±0.49 Figure 2The clinical significance of FLJ33360 in ovarian cancer.**Notes:** (**A**) The expression profile of FLJ33360 based on the GEPIA database. (**B**) Differential expression of FLJ33360 between ovarian cancer and healthy ovarian tissues based on the GEPIA database. \**P*\<0.05. (**C**) Differential expression of FLJ33360 in stage II, stage III and stage IV ovarian cancer. (**D**) The relationship between FLJ33360 expression and PFS of ovarian cancer patients based on the KM Plotter. (**E**) Differential expression of FLJ33360 based on qRT-PCR. (**F**) ROC curve of FLJ33360 based on qRT-PCR.**Abbreviations:** OV, ovarian cancer; GEPIA, gene expression profiling interactive analysis; PFS, progression-free survival; KM, Kaplan-Meier; qRT-PCR, quantitative reverse transcription polymerase chain reactions; ROC, receiver operating characteristic.

Prediction of miRNAs that interact with FLJ33360 {#S0003-S2002}
------------------------------------------------

DIANA IncBase v2, miRDB, RegRNA2.0 and IncRNAMap predicted 37, 152, 83 and 127 miRNAs that may interact with FLJ33360, respectively. A Venn diagram ([Figure 3](#F0003){ref-type="fig"}) showed that two intersections of miRNAs are jointly predicted by the four algorithms: miR-30b-3p and miR-4755-3p.Figure 3A flow chart to screen the miRNAs based on Venn diagrams.

Verification of the differential expression of the two miRNAs in ovarian cancer {#S0003-S2003}
-------------------------------------------------------------------------------

To verify the differential expression of miR-30b-3p and miR-4755-3p in ovarian cancer, we performed a meta-analysis of eight eligible microarray datasets in GEO (GSE31568, GSE53829, GSE61741, GSE48485, GSE58517, GSE67329, GSE83693, and GSE76449) and 1 dataset in ArrayExpress (E-MTAB-4667). The characteristics of the selected datasets are shown in [Table 2](#T0002){ref-type="table"}. In total, 222 ovarian cancer samples and 103 control samples were included. In the meta-analysis, the heterogeneity between the miR-30b-3p-related datasets was small (*P*=0.325, I^2^=12.8%); therefore, the fixed effects model was selected to calculate the combined standard mean difference (SMD). The pooled SMD of miR-30b-3p was 0.44 (95% CI: 0.19--0.69, *P*=0.001) ([Figure 4A](#F0004){ref-type="fig"}). Heterogeneity was observed between the miR-4755-3p-related datasets (*P*=0.081, I^2^=55.4%), and the random effect model was used to calculate the pooled SMD of miR-4755-3p, which was 0.69 (95% CI:-0.25--1.62, *P*=0.149) ([Figure 4B](#F0004){ref-type="fig"}). In addition, the funnel plot showed no significant publication biases in these datasets ([Figure 4C](#F0004){ref-type="fig"} and [D](#F0004){ref-type="fig"}). The results indicated that miR-30b-3p was significantly upregulated in ovarian cancer, while the difference in miR-4755-3p expression was not significant. We selected miR-30b-3p as an important miRNA that competitively binds to FLJ33360 in ovarian cancer.Table 2Characteristics of the datasets included in the meta-analysisSeriesCountryYearPlatformSample sourceOV samplesNormal samplesGSE31568Germany2011GPL9040Peripheral blood1519GSE53829China2014GPL18138Tissue3914GSE61741Germany2014GPL9040Peripheral blood2426GSE48485Germany2014GPL14943Peripheral blood55GSE58517China2015GPL18402Urine55GSE67329USA2015GPL8179Cell52GSE76449USA2016GPL19117Cell122GSE76449USA2016GPL19117Exosomes122GSE83693South Korea2017GPL22079Tissue44E-MTAB-4667Italy2017NRPeripheral blood10124[^1] Figure 4Meta-analysis of the differential expression of miR-30b-3p and miR-4755-3p between the ovarian cancer group and the control group based on GEO and ArrayExpress datasets.**Notes:** (**A**) Forest plot of studies evaluating the SMD of miR-30b-3p (a fixed effects model). (**B**) Forest plot of studies evaluating the SMD of miR-4755-3p (a random effects model). (**C**) Funnel plot of miR-30b-3p-related datasets. (**D**) Funnel plot of miR-4755-3p-related datasets.**Abbreviations:** GEO, gene expression omnibus; SMD, standard mean difference.

Acquisition of target genes in ovarian cancer {#S0003-S2004}
---------------------------------------------

MiRDB, miRMap, miRWalk, DIANA Tarbase v8 and miRTarBase predicted 1096, 6755, 4570, 394 and 667 mRNAs targeted by miR-30b-3p, respectively. The Venn diagram ([Figure 5](#F0005){ref-type="fig"}) showed that at least two algorithms repeatedly predicted 3355 target genes. To further identify target genes that are differentially expressed in ovarian cancer, we extracted a total of 6434 mRNAs that are differentially expressed in ovarian cancer and healthy ovarian tissues from the dataset GSE14407. The expression levels of 696 mRNAs showed greater than 2-fold decreases (adj. *P*-value\<0.05, log2FC\<-2.0). The above 3355 mRNAs and 696 mRNAs were combined to obtain 104 potential genes that were targeted by miR-30b-3p in ovarian cancer.Figure 5A flow chart to screen the mRNAs based on Venn diagrams.

Functional analysis of target genes in ovarian cancer {#S0003-S2005}
-----------------------------------------------------

GO analysis provides a biological functional interpretation of a large number of genes derived from genomic studies. GO analysis of the 104 target genes revealed some of the biological processes involved, such as positive regulation of smooth muscle cell migration, the unsaturated fatty acid metabolic process, and positive regulation of the epithelial to mesenchymal transition ([Table 3](#T0003){ref-type="table"}, [Figure 6A](#F0006){ref-type="fig"}). The enriched KEGG pathways included the AGE-RAGE signalling pathway in diabetic complications and colorectal cancer ([Table 4](#T0004){ref-type="table"}, [Figure 6B](#F0006){ref-type="fig"}). The PPI network revealed interactions between target genes ([Figure 7A](#F0007){ref-type="fig"}). Among them, BCL2 and DLG2 are hub genes. Based on the GEPIA database, we examined the expression levels of these two genes. BCL2 and DLG2 expression levels were both significantly downregulated in ovarian cancer (*P*\<0.05, [Figure 7B](#F0007){ref-type="fig"} and [C](#F0007){ref-type="fig"}). In addition, we extracted the expression levels of FLJ33360, BCL2 and DLG2 in ovarian cancer patients in the TCGA database. Pearson correlation analysis results showed a positive correlation between FLJ33360 and BCL2 (r=0.134, *P*=0.014, [Figure 7D](#F0007){ref-type="fig"}) but no significant correlation between FLJ33360 and DLG2 (r=−0.032, *P*=0.555, [Figure 7E](#F0007){ref-type="fig"}).Table 3Enrichment GO terms of the target genesGO IDTermOntologyCount*P*-valueGO:0014911positive regulation of smooth muscle cell migrationBP44.66E-05GO:0006582melanin metabolic processBP31.91E-04GO:0043244regulation of protein complex disassemblyBP52.42E-04GO:0033559unsaturated fatty acid metabolic processBP53.57E-04GO:0048821erythrocyte developmentBP35.62E-04GO:0006692prostanoid metabolic processBP31.41E-03GO:0010718positive regulation of epithelial to mesenchymal transitionBP31.74E-03GO:0050918positive chemotaxisBP37.01E-03GO:0002088lens development in camera-type eyeBP37.56E-03GO:0048332mesoderm morphogenesisBP37.85E-03[^2] Table 4KEGG pathway enrichment analysis of the target genesKEGG IDKEGG termCount*P*-valueGene symbolKEGG:04933AGE-RAGE signaling pathway in diabetic complications46.45E-03AKT3, BCL2, TGFBR2, THBDKEGG:05210Colorectal cancer31.68E-02AKT3, BCL2, TGFBR2[^3] Figure 6GO and KEGG analysis of potential target genes using the Cytoscape plug-in GluGO.**Notes:** (**A**) A functional network of GO terms. (**B**) KEGG pathways displayed as an interaction network.**Abbreviations:** GO, gene ontology; KEGG, Kyoto encyclopedia of genes and genomes.Figure 7BCL2 is the hub gene of potential target genes.**Notes:** (**A**) The PPI network of the target genes. Nodes represent gene-encoded proteins. Connections between nodes represent the relationship between proteins. A bold line indicates a higher confidence level. (**B**) Differential expression of BCL2 between ovarian cancer and healthy ovarian tissues based on the GEPIA database. \**P*\<0.05. (**C**) Differential expression of DLG2. \**P*\<0.05. (**D**) The correlation between FLJ33360 and BCL2 based on the TCGA database. (**E**) The correlation between FLJ33360 and DLG2.**Abbreviations:** PPI, protein-protein interaction; GEPIA, gene expression profiling interactive analysis; TCGA, the cancer genome atlas.

Discussion {#S0004}
==========

The high recurrence rate and mortality of ovarian cancer are major problems worldwide. New biomarkers and therapeutic targets are urgently needed to improve the status quo.[@CIT0023] The mechanism and function of lncRNA are increasingly being explored and elucidated. Many studies have shown that lncRNAs containing sequences similar to their target miRNAs can be used to isolate miRNAs from mRNAs to further regulate gene expression and participate in the development and progression of various types of tumours.[@CIT0024] The discovery of aberrantly expressed lncRNAs and related signalling pathways is important for improving the status of ovarian cancer.[@CIT0025] In this study, we first determined the change in expression of lncRNA FLJ33360. A large amount of data indicates that FLJ33360 expression is significantly downregulated in ovarian cancer, especially in high-grade serous carcinoma. As the disease stage progresses, the downregulation of FLJ33360 is significant. In addition, low FLJ33360 expression is associated with high recurrence in ovarian cancer patients and may serve as a potential biomarker for prognostic evaluation of ovarian cancer. FLJ33360 may also have potential for detecting ovarian cancer. In our follow-up study, we will investigate whether FLJ33360 is differentially expressed in blood between ovarian cancer patients and normal controls.

To explore the underlying pathways of FLJ33360 in ovarian cancer to further understand its mechanism, based on the interaction between miRNAs and lncRNAs, this study screened two miRNAs that interact with the lncRNA FLJ33360: miR-30b-3p and miR-4755-3p. Our study has shown that FLJ33360 is significantly downregulated in ovarian cancer. Based on the meta-analysis results, we excluded miR-4755-3p from the angle of ceRNA role of lncRNA. miR-30b-3p has been reported to play an important role in human cancer.[@CIT0026] This study found for the first time that miR-30b-3p is significantly upregulated in ovarian cancer, and that FLJ33360 downregulates the expression of target genes by competitive binding of miR-30b-3p. These target genes are enriched in many different biological processes and signalling pathways, including positive regulation of smooth muscle cell migration, the unsaturated fatty acid metabolic process, and positive regulation of the epithelial to mesenchymal transition. Notably, FLJ33360 was not identified among the validated targets of miR-30b-3p, possibly because FLJ33360 belongs to the lncRNA category and is not present in the mRNA library of the miRNA-predicted mRNA module in the prediction algorithms used in this study. BCL2 is the hub gene of these target genes. The expression of BCL2 is upregulated in most tumour tissues and promotes tumour development by inhibiting apoptosis.[@CIT0027] However, many studies have shown a decrease in BCL2 expression in ovarian cancer,[@CIT0028],[@CIT0029],[@CIT0030],[@CIT0031] which is consistent with the results of this study. The mechanism of action of BCL2 in ovarian cancer is complex.[@CIT0032] On the one hand, regulation of the BCL2 family, especially individual proteins, in ovarian cancer cell apoptosis appears to be tissue-specific.[@CIT0031],[@CIT0033] On the other hand, in addition to acting as a regulator of apoptosis in ovarian cancer, BCL2 may have other effects,[@CIT0029] such as inhibiting angiogenesis[@CIT0028],[@CIT0030] and preventing cells from entering the S phase, leading to specific growth inhibition.[@CIT0030] Other researchers have also pointed out that frequent apoptosis in ovarian cancer is a sign of high conversion of invasive malignant cells and may play a role in eliminating cells that carry DNA damage and in transforming these cells into cancer cells.[@CIT0032] Taken together, FLJ33360 may regulate the expression of target genes such as BCL2 to participate in different biological processes via sponging miR-30b-3p in ovarian cancer.

Conclusion {#S0005}
==========

We found that FLJ33360 expression was significantly downregulated in ovarian cancer and was closely related to the clinical stage and recurrence of the disease. FLJ33360 appears to be a potential biomarker for early diagnosis and prognostic assessment in ovarian cancer. FLJ33360 may be involved in multiple biological pathways in ovarian cancer by competitively binding to miR-30b-3p, thus warranting in-depth studies with in vitro and in vivo experiments. This study provides new insights into the clinical significance and mechanism of action of FLJ33360 in ovarian cancer and may reveal new targets for future research and treatment.
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